A new research article on the identification of IDH mutation and two other important mutations in brain tumors has been published! Ismaïl Hermelo and others utilized patient-derived glioma organoids, which allowed for a large number of samples in comparison to using only samples collected from patients, while retaining sample-specific features. DMS’s suitability for identifying IDH-mutation was validated, and results regarding the other mutations (1p/19q codeleted and CDKN2A/B loss) showed promising results as well. Classification accuracy for IDH-mutant versus IDH wild-type was 90%, with 91% sensitivity and 89% specificity.

The paper has been published in the Journal of Neuro-Oncology as open access! You can read the full text here.